Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Chevron Reportedly In Talks To Extend Current CEO’s Retirement Age – $CVX $DIA $INVO

By John F. Heerdink, Jr.

Reportedly, the board of Chevron Corporation (CVX ) is in talks to extend the mandatory retirement age of its Chief Executive Officer Mike Wirth. Mike Wirth has been the board chairman and chief executive officer of Chevron since 2018 and will reach the company’s fixed retirement age of 65 in late 2025. 

The board members believe the company does not have any internal candidates to succeed Wirth and the extension will allow him to prepare someone to succeed him. Wirth has been with Chevron since 1982.

Dow 30 component Chevron Corporation (CVX), through its subsidiaries, engages in integrated energy, chemicals, and petroleum operations worldwide.  To learn more about Chevron (CVX) and to track their progress please visit the Vista Partners Chevron Page.

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also provides select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives. 


We at Vista see this as an incredible time to consider investing into the fertility space in general. The multi-billion-dollar global fertility market is currently predicted to reach approximately US$47.9 billion by 2030 with the massively underserved patient market still unable to access affordable treatment. It is estimated that approximately 90% of patients go without care annually.  If you have ever struggled with infertility issues, or know someone who has, you are probably well aware of how demoralizing it can be. Imagine for a moment spending thousands of dollars and months of intensive medical procedure only to end up empty handed, exhausted, sad, and defeated because after all of that time, work, and money, you still don’t have a baby. That’s an incredibly difficult situation, and it’s becoming more common each passing year. Likewise, the need for more effective, less invasive infertility treatment options is increasing with each passing year. This is the sole focus of medtech company INVO Bioscience (NASDAQ: INVO). INVO’s mission is to help people realize the dream of parenthood by increasing worldwide access to an efficient, effective, and connected experience in reproductive treatment. The company offers a safe, effective, and more natural way for women to address infertility issues. Their patented and FDA-cleared medical device, INVOcell (pictured above), holds the eggs and sperm within the woman’s body during fertilization and early embryo development: a safe, intimate way for women to be connected right from the very beginning. This differs from IVF in that the fertilization takes place in vivo (inside the woman’s body): hence the company’s trademark for INVOcell, Life Begins Within™ and reduces and/or eliminates the need of expensive labs and monitoring that is needed for IVF. INVO Bioscience is leading the way for an infertility treatment that’s effective and more natural than traditional IVF. Learn more now by reading our latest PROGRESS REPORT by clicking here. 

Meet the first and only FDA-cleared and CE-marked medical device, INVOcell, for fertility treatment through intravaginal culture (IVC).

The fertility journey is difficult in so many ways. But INVOcell’s unique approach creates efficiencies — which mean opportunities — for more people to receive treatment around the world.
(Read Original Story: UPDATE 1-Chevron considers extending current CEO's retirement age - WSJ in Reuters)


Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us